CeriBell (NASDAQ:CBLL) Now Covered by Bank of America

Bank of America initiated coverage on shares of CeriBell (NASDAQ:CBLL) in a research note released on Tuesday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $32.00 price objective on the stock.

CBLL has been the topic of several other research reports. William Blair began coverage on CeriBell in a research note on Tuesday. They set an “outperform” rating on the stock. TD Cowen started coverage on shares of CeriBell in a research note on Tuesday. They set a “buy” rating and a $31.00 target price on the stock. Canaccord Genuity Group assumed coverage on shares of CeriBell in a research note on Tuesday. They issued a “buy” rating and a $30.00 price target for the company. Finally, JPMorgan Chase & Co. initiated coverage on CeriBell in a research note on Tuesday. They set an “overweight” rating and a $32.00 target price for the company. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $31.00.

CeriBell Trading Up 2.7 %

CeriBell stock opened at $26.96 on Tuesday. CeriBell has a fifty-two week low of $23.00 and a fifty-two week high of $27.71.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.